Outcomes of Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias

BACKGROUND: Philadelphia chromosome-positive (Ph+) advanced leukemias including acute myeloid leukemia (AML) and chronic myeloid leukemia myeloid blast phase (CML-MBP) have poor outcomes. Venetoclax (VEN) has shown synergism with BCR-ABL1 tyrosine kinase inhibitors (TKI) in pre-clinical studies. How...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Acta Haematol
Main Authors: Maiti, Abhishek, Franquiz, Miguel, Ravandi, Farhad, Cortes, Jorge E., Jabbour, Elias J., Sasaki, Koji, Marx, Kayleigh, Daver, Naval G., Kadia, Tapan M., Konopleva, Marina Y., Masarova, Lucia, Borthakur, Gautam, DiNardo, Courtney D., Naqvi, Kiran, Pierce, Sherry, Kantarjian, Hagop M., Short, Nicholas J.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7839068/
https://ncbi.nlm.nih.gov/pubmed/32289808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000506346
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares